Evaluation the clinical efficacy and safety profile of glucocorticosteroid combined with oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F) in the treatment of patients with lupus nephritis. Open-labeled, randomized, prospective multi-center clinical trial. Observation period of 24 weeks.
No linked publications found in PubMed
Inclusion Criteria: * Age 18-65 years with informed consent * SLE defined by meeting 4 or more ACR classification criteria * Biopsy-proven active proliferative lupus glomerulonephritis ISN classification Class III or IV * Active renal disease Exclusion Criteria: * Pregnant, lactating or further fertility requirements * Serum creatinine \> 3 mg/dL * Serum ALT or AST \> 3 times upper limit of normal * Severe, progressive renal, hepatic, hematological, gastrointestinal, pulmonary, cardiovascular, neurological, endocrine or cerebral disease * Previous treated with cyclophosphamide or T2. * Not discontinuing MMF, azathioprine, leflunomide, methotrexate, calcineurin inhibitor before 1 month of randomization. * Active or chronic infection, including HIV, HCV, HBV, tuberculosis * Patient with malignancy